Azitra plans first human study of ATR-COSF anti-wrinkle product, expects initial data by year-end
AZTR•Azitra said its ATR-COSF cosmetic candidate reduced the appearance of fine lines and wrinkles in human skin samples. It plans a first-in-human study of about 30 participants, with initial results expected by year-end 2026.
1. Study plans
Azitra said ex vivo tests found its ATR-COSF cosmetic candidate reduced the appearance of fine lines and wrinkles in human skin samples. The higher-concentration formulation improved skin elasticity compared with the lower concentration and hydrogel control. The company plans a first-in-human study of approximately 30 participants, with initial results expected by year-end 2026.
2. Results presentation
Azitra plans to present detailed ex vivo results at BIO-Europe in Cologne, Germany, on November 10, 2026.
